Cargando…
Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact
BACKGROUND: In a recent article in The Lancet, Protopopoff et al. stated that insecticide resistance must be tackled and concluded that adding the insecticide synergist piperonyl butoxide (PBO) to a bed net with a pyrethroid as principal insecticide might be a part of the response. MAIN TEXT: The st...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271413/ https://www.ncbi.nlm.nih.gov/pubmed/30501617 http://dx.doi.org/10.1186/s12936-018-2596-7 |
_version_ | 1783376923263500288 |
---|---|
author | Skovmand, Ole |
author_facet | Skovmand, Ole |
author_sort | Skovmand, Ole |
collection | PubMed |
description | BACKGROUND: In a recent article in The Lancet, Protopopoff et al. stated that insecticide resistance must be tackled and concluded that adding the insecticide synergist piperonyl butoxide (PBO) to a bed net with a pyrethroid as principal insecticide might be a part of the response. MAIN TEXT: The study in Tanzania compares malaria prevalence between users of two different nets with the principal insecticide permethrin: Olyset and Olyset Plus (Olyset+), the latter also holding the synergist molecule PBO, the first not. The article is based on randomized cluster trial of very high quality, but Olyset+ exposes much more permethrin at the surface so the higher efficacy may not be because of the added PBO. CONCLUSION: Data published by the World Health Organization (WHO) when evaluating Olyset+ as well of the study of Protopopoff et al. showed that much more permethrin is available on the surface of Olyset+ than on the surface of Olyset and the relatively small and rapidly dwindling dosage of PBO may have nothing to do with the superior effect of Olyset+. The WHO should not change politics for “PBO nets” based on this study alone. |
format | Online Article Text |
id | pubmed-6271413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62714132018-12-05 Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact Skovmand, Ole Malar J Opinion BACKGROUND: In a recent article in The Lancet, Protopopoff et al. stated that insecticide resistance must be tackled and concluded that adding the insecticide synergist piperonyl butoxide (PBO) to a bed net with a pyrethroid as principal insecticide might be a part of the response. MAIN TEXT: The study in Tanzania compares malaria prevalence between users of two different nets with the principal insecticide permethrin: Olyset and Olyset Plus (Olyset+), the latter also holding the synergist molecule PBO, the first not. The article is based on randomized cluster trial of very high quality, but Olyset+ exposes much more permethrin at the surface so the higher efficacy may not be because of the added PBO. CONCLUSION: Data published by the World Health Organization (WHO) when evaluating Olyset+ as well of the study of Protopopoff et al. showed that much more permethrin is available on the surface of Olyset+ than on the surface of Olyset and the relatively small and rapidly dwindling dosage of PBO may have nothing to do with the superior effect of Olyset+. The WHO should not change politics for “PBO nets” based on this study alone. BioMed Central 2018-11-30 /pmc/articles/PMC6271413/ /pubmed/30501617 http://dx.doi.org/10.1186/s12936-018-2596-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Opinion Skovmand, Ole Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact |
title | Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact |
title_full | Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact |
title_fullStr | Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact |
title_full_unstemmed | Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact |
title_short | Comparing the un-comparable: Olyset Plus and Olyset, different malaria impact |
title_sort | comparing the un-comparable: olyset plus and olyset, different malaria impact |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271413/ https://www.ncbi.nlm.nih.gov/pubmed/30501617 http://dx.doi.org/10.1186/s12936-018-2596-7 |
work_keys_str_mv | AT skovmandole comparingtheuncomparableolysetplusandolysetdifferentmalariaimpact |